Real-World Outcomes of First-Line Rituximab in Immune Thrombotic Thrombocytopenic Purpura. (PubMed, Clin Lab) - Oct 9, 2026 - "First-line rituximab treatment can reduce mortality and relapse rates in iTTP patients, improve sur-vival outcomes, and demonstrates good safety."
Journal • Real-world evidence • Retrospective data • Allergy • Hematological Disorders • Infectious Disease • Rare Diseases • Thrombocytopenic Purpura • CD4 • CD8
|
|
Aosen Dong; Jia Wang; Yi Dong; Yuanyuan Shen
|